About me
Dr. Chul Kim is the Director of Thoracic Oncology at MedStar Georgetown University Hospital and an Associate Professor at Georgetown University with a focus on thoracic oncology. His goal as a thoracic medical oncologist is to introduce innovative cancer therapies into clinical practice, and he is devoted to formulating clinical trials aimed at promoting personalized cancer treatments.
Dr. Kim's academic journey began at the Sungkyunkwan University School of Medicine in Seoul, South Korea, where he graduated Summa Cum Laude. He furthered his studies at the Harvard School of Public Health, obtaining a Master’s degree in Public Health. His medical training continued at the University of Minnesota where he trained in internal medicine. Later, he became a clinical fellow in hematology and oncology at the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
In 2018, Dr. Kim was honored with the Norman Rales Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). In 2021, he received the John F. Potter, MD, Award from Georgetown Lombardi Comprehensive Cancer Center.
Dr. Kim has authored more than 60 articles in reputable peer-reviewed journals, including Lancet Oncology, JAMA Oncology, Journal of Thoracic Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. Additionally, he has served as a reviewer for various journals such as Journal of Clinical Oncology, Clinical Lung Cancer, Lancet HIV, Lancet Haematology, and JCO Precision Oncology.
He is an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
Driven by his commitment to patient care, Dr. Kim aims to provide the best possible treatment options for his patients. In his free time, he enjoys hiking, exploring diverse cuisines, and traveling with his wife and son.
Clinical areas of focus
- Blood Clotting Disorder Treatment
- Internal Radiation Therapy
- Lung Cancer Treatment
- Mesothelioma
- Pleural Cancer Treatment
- Pulmonary Nodules
- Small Cell Lung Cancer
- Small Cell Lung Cancer Treatment
- Thymoma Treatment
- Thymus Cancer
- Thymus Cancer Treatment
- Transitional Cell Carcinoma Treatment
Conditions and procedures
Conditions I treat
- Accessory Sinuses Cancer
- Adenocarcinoma Of Lung
- Anemia
- Aplastic Anemia
- Aplastic Anemias And Bone Marrow Failure Syndromes
- Basal Cell Carcinoma Of Skin
- Benign Neoplasm Of Kidney
- Benign Neoplasm Of Skin
- Bladder Carcinoma
- Bleeding Disorders
- Bone Cancer
- Bone Discontinuity
- Brain Tumor
- Capillary Diseases
- Chronic Eosinophilic Leukemia
- Colon Cancer
- Common Variable Immunodeficiency
- Complications Of Infusion, Transfusion And Injection
- Cutaneous Melanoma
- Disorders Of Carbohydrate Metabolism
- Disorders Of Mineral Metabolism
- Esophagus Cancer
- Family History Of Malignant Neoplasm
- Gastric Cancer
- Heart Cancer
- Hemorrhagic Conditions
- Hodgkin Disease
- Intrahepatic Bile Ducts Cancer
- Kaposi's Sarcoma
- Larynx Cancer
- Liposarcoma
- Liver Cancer
- Lung Cancer
- Malaise And Fatigue
- Malignant Neoplasm
- Malignant Neoplasm Of Bladder
- Malignant Neoplasm Of Cervix Uteri
- Malignant Neoplasm Of Connective And Soft Tissue
- Malignant Neoplasm Of Endocrine Glands
- Malignant Neoplasm Of Heart, Mediastinum And Pleura
- Malignant Neoplasm Of Lymph Nodes
- Malignant Neoplasm Of Ovary
- Malignant Neoplasm Of Retroperitoneum
- Malignant Neoplasm Of Spinal Cord
- Malignant Neoplasm Of Testicle
- Malignant Neuroendocrine Tumors
- Merkel Cell Carcinoma
- Mesothelioma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Neoplasms
- Myopathies
- Nasopharynx Cancer
- Neoplasm Analysis
- Neoplasm Of Uncertain Behavior
- Neoplasms Of Lymphoid, Hematopoietic And Related Tissue
- Neutropenia
- Noninfective Gastroenteritis
- Ovarian Cancer
- Pancreas Cancer
- Papillary Carcinoma Of Breast
- Pericardium Diseases
- Personal History Of Medical Treatment
- Plasma Cell Neoplasms
- Prostate Cancer
- Pulmonary Embolism
- Pulmonary Nodules
- Respiratory Conditions Due To External Agents
- Retroperitoneal Cancer
- Secondary Lymph Node Cancer
- Secondary Malignant Neoplasm Of Brain
- Sickle Cell Anemia
- Skin Cancer
- Small Cell Lung Cancer
- Small Intestine Cancer
- Stomach Cancer
- Subclinical Hypothyroidism
- Thrombocytopenia
- Thymus Cancer
- Thyroid Cancer
- Tongue Cancer
- Tonsil Cancer
- Transitional Cell Carcinoma
- Transplanted Organ And Tissue Status
- Uterine Cancer
- Venous Embolism
- Vulvar Cancer
- Waldenstrom Macroglobulinemia
Procedures I perform
- A1c Testing
- Adrenal Antibody Testing
- Antiangiogenic Therapy
- Antineoplastic Injection
- Arthrocentesis
- Blood Banking
- Blood Clot Treatment
- Blood Clotting Disorder Treatment
- Blood Transfusion
- Bone Cancer Staging
- Bone Marrow Biopsy
- Bone Marrow Biopsy And Aspiration
- Bone Marrow Failure Treatment
- Brca Gene Testing
- Cancer Awareness
- Cancer Education Consultation
- Cancer Immunotherapy
- Cancer Nutrition Counseling
- Cancer Pain Management
- Cancer Psychological Counseling
- Cancer Quality Metrics
- Cancer Reconstruction Surgery
- Cancer Registry Management Consultation
- Cancer Rehabilitation
- Cancer Research Institute
- Cancer Risk Assessment
- Cancer Social Work Management
- Cancer Support
- Cancer Treatment
- Cancer Treatment Monitoring
- Cardiac Cell Therapy
- Care Coordination Consultation
- Case Management
- Case Management Consultation
- Cervical Lymph Node Dissection
- Chemotherapy Administration
- Clinical Trials Management Consultation
- Clinical Trials Participation
- Community Health
- Computerized Tomography (CT) Scan
- Deep Vein Thrombosis Management
- Dopamine Therapy
- Fertility Counseling
- Fine Needle Aspiration Biopsy
- Flow Immunophenotyping
- Fluorescence In Situ Hybridization
- Genetic Counseling
- Genetic Mutation Testing
- Genomic Testing For Cancer
- Geriatric Oncology Consultation
- Gynecologic Oncology Consultation
- Gynecological Cancer Screening
- Hematology Consultation
- Hormone Replacement Therapy
- Hospice Care Referral
- Immune Cell Therapy Administration
- Immunodeficiency Treatment
- Immunohistochemistry Staining
- Immunotherapy
- Infectious Disease Treatment
- Internal Jugular Central Line Placement
- Internal Radiation Therapy
- Introduction Of Antineoplastic
- Kinesiology Analysis
- Leukemia Treatment
- Leukopenia Treatment
- Liver Biopsy
- Liver Tumor Ablation
- Lumbar Puncture
- Lung Cancer Treatment
- Lymph Node Biopsy
- Lymphoma Treatment
- Magnesium Imbalance Treatment
- Magnetic Resonance Imaging (MRI)
- Mep (MOTOR EVOKED POTENTIALS)
- Mesenteric Angiography
- Methylation Profiling
- Molecular Diagnostics
- Multiple Myeloma Treatment
- Nausea And Vomiting Management
- Nausea And Vomiting Management Consultation
- Non-Small Cell Lung Cancer Treatment
- Orthopedic Physical Therapy
- Pain Management Consultation
- Pain Medication Management
- Palliative Care
- Palliative Care Consultation
- Palliative Care Coordination
- Palliative Care Education
- Parotid Biopsy
- Pathology Consultation
- Patient Navigation
- Pediatric Advocacy
- Pediatric Oncology Consultation
- Peer Support Groups
- Percutaneous Kyphoplasty
- Percutaneous Tumor Chemoembolization
- Peripheral Blood Stem Cell Transplantation
- Plasma Cell Disorder Treatment
- Pleural Cancer Treatment
- Proton Beam Radiosurgery
- Psa Testing
- Pulmonary Embolism Treatment
- Pulmonary Nodule Treatment
- Radiation Therapy
- Removal Of Central Venous Access Device
- Salvage Surgery
- Sentinel Lymph Node Mapping
- Sickle Cell Anemia Treatment
- Single Photon Emission Computed Tomography
- Small Cell Lung Cancer Treatment
- Soft Tissue Neck Ct Without Contrast
- Surgical Oncology Consultation
- Surgical Oncology Surgery
- Thrombophilia Management
- Thymoma Treatment
- Thymus Cancer Treatment
- Transitional Cell Carcinoma Treatment
- Tumor Debulking
- Tumor Embolization
- Tumor Immunohistochemistry
- Tumor Marker Testing
- Tumor Registry
- Tumor Resection
- Urologic Oncology Consultation
- Vaccine Development And Policy
- Venous Access Device Irrigation
- Venous Access Device Removal
- Wellness Services
- Whole Breast Radiation Therapy
- Whole-Exome Sequencing
Insurance
MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.
-
List of insurance plans we accept
- CIGNA Indemnity
- Employee Health Plan
- Navigate
- United Healthcare Choice
- Tricare Reserve Select
- United Healthcare Select HMO-EPO/NPP Cardiac Global
- Mamsi Life & Health (Indem./PPO)
- Maryland Physicians Care MCO
- Cigna Preferred Medicare (HMO)
- Aetna Elect Choice/ Open Access (POS)
- CareFirst BlueChoice HMO
- UnitedHealthcare Individual Exchange Plans
- WellPoint Maryland - Maryland Health Choice
- Anthem BCBS of VA HealthKeepers (POS & POS OA)
- Aetna Open Choice (PPO)
- CareFirst Administrators
- HUMANA/Choice Care Medicare Plans (Choice, Gold Choice)
- Veterans Affairs Community Care Network
- CareFirst Blue Choice Opt Out Plus Open Access (POS)
- UnitedHealthcare and AARP Medicare Complete Plans
- CIGNA Connect EPO
- MedStar Family Choice DC Healthcare Alliance
- United Healthcare Options (PPO)
- Options PPO Cardiac Global
- Aetna Medicare Advantage HMO & PPO Plans
- Great-West Healthcare POS/CIGNA
- Network OA
- First Health PPO
- TRICARE East Prime
- Coventry Health Care of Virginia
- Optimum Choice & Optimum Choice Preferred (POS) Cardiac Global
- Priority Partners - Maryland Health Choice
- Core Essential (HMO)
- Private Health Care Systems (PPO)
- Aetna Better Health of VA
- CareFirst MedStar PPO
- Police and Fire Clinic
- Kaiser Permanente Medicare Plus
- CIGNA SureFit (HMO)
- Health Services for Children with Special Needs
- Uniformed Services Family Health Plan
- Beech Street PPO
- BlueChoice Open Access
- CareFirst Blue Preferred PPO
- M.D. IPA Preferred (POS)
- Aetna Advantage 6350
- CareFirst BlueCross BlueShield Advantage Core/Enhanced
- Optima Family Care MCO - VA Medicaid MCO
- IH-POS
- POS OA
- Humana Gold Plus HMO
- Geisinger Medicare Advantage
- Aetna Medicare Advantage PFFS Plan
- Anthem BCBS of VA HealthKeepers Plus
- Kaiser Permanente Signature - Added Choice
- Kaiser Permanente Select Cardiac Global
- CareFirst (NCA) Indemnity
- United Healthcare Choice Plus
- IH-Open POS Plus
- AmeriHealth Caritas DC Healthy Families
- Fee-for-Service (FFS) District of Columbia, Maryland and Virginia Medicaid
- Aetna Signature Administrator PPO/TPA
- Aetna Classic 3500
- Select HMO/HealthFund/Health Network
- MD IPA (HMO) & MD IPA Preferred Cardiac Global
- Choice POS II Open Access
- Cigna Achieve Medicare (HMO C-SNP)
- Aetna Managed Choice (POS)
- Amerigroup DC Alliance
- Cigna Alliance Medicare (HMO)
- MedStar Family Choice DC Healthcare Alliance
- HumanaChoice PPO
- Kaiser Permaenete Signature - Added Choice Cardiac Global
- IH-POS Plus
- IH-HMO
- MultiPlan, Inc
- DC/MD SHOP QHP Small Business Plans
- CareFirst Maryland Point of Service Plan
- UnitedHealthcare Medicare Adv. Special Needs Plans
- IH-EPO Plus
- CareFirst NASCO
- CareFirst Group Medicare Advantage
- Aetna Traditional Choice (PPO)
- UHC Passport
- United Healthcare Navigate Cardiac Global
- CareFirst MedStar Select PPO
- Coventry Health Care National Network PPO
- CIGNA PPO
- OA Plus
- BCBS Out-of-State Medicare Plans (Blue Advantage)
- CIGNA PPO Plus
- BCBS of Michigan (BCN Advantage,Security Blue, Freedom, Medicare PLUS Blue Group PPO)
- UnitedHealthcare Individual Exchange Plans
- IH-Open EPO Plus
- Anthem BCBS Medi Blue SNP
- Aetna Basic
- CIGNA EPO
- Medicare FFS
- CIGNA HMO Open Access
- Choice Fund PPO
- Johns Hopkins Advantage MD PLUS PPO
- Kaiser Permanente Medicare Advantage Signature and Select
- IH-Open HMO
- Anthem BCBS Medi Blue Dual Adv
- Healthy Blue (HMO, POS)
- CareFirst EPO
- UnitedHealthcare Medicare Advantage DSNP District of Columbia
- United Healthcare Community Plan - VA Medicaid MCO
- United Healthcare Choice Cardiac Global
- Kaiser Permanente HMO Plus and DHMO Plus Member
- Medicare Direct
- CareFirst Blue Card Program
- Medicare Advantage - Advantra Value (PPO)
- Kaiser Maryland Medicaid MCO
- United Student Resources
- Aetna Classic 5000
- CareFirst Group Medicare Advantage prescription drug benefit (PPO)
- First Health PPO
- Aetna Premier 200PD
- Kaiser Permanente Flexible Choice 3-tier POS
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Cigna TotalCare (HMO D-SNP)
- OCI Direct (HMO)
- Erickson Advantage Plans
- Kaiser Permanente Select
- Humana Medicare Advantage - HMO Open Access
- Aetna Classic 5000PD
- MedStar Family Choice - Maryland Health Choice
- CareFirst Community Health Plan of MD
- Lasso Healthcare - Medicare Medical Savings Account
- Aetna Quality Point of Service (POS)
- CIGNA POS/Network POS
- HumanaChoice Honor's plan PPO
- Aetna Worker's Compensation Network
- CareFirst Dual Prime HMO-SNP
- Jai Medical Systems - Maryland Health Choice
- IH-PPO
- Amerigroup DC Healthy Families
- AmeriHealth Caritas DC Healthcare Alliance
- Kaiser Permanente Flexible Choice POS Cardiac Global
- CareFirst FEP Blue Focus
- Aetna Elect Choice/ EPO (Aetna Health Fund)
- Mamsi Life & Health (Indem./PPO) Cardiac Global
- Aetna Advantage 6350PD
- CareFirst Maryland Indemnity or PPO
- Fee-for-Service (FFS) District of Columbia, Maryland and Virginia Medicaid
- United Medicare Private Fee-for-Service (PFFS) plans
- TRICARE for Life East
- Aetna VA Exchange
- IH-Open HMO Option
- Coventry of Delaware HMO/PPO
- Aetna Student Health Insurance
- IH-Network Only Plus
- HealthyBlue PPO
- Optimum Choice Preferred (POS)
- Anthem Federal Employee Program Standard
- M.D. IPA (HMO)
- Aetna Better Health of MD
- Cigna True Choice Plus Medicare (PPO)
- Johns Hopkins Advantage MD HMO
- Private Fee-for-Service Plans (PFFS)
- Optimum Choice
- CIGNA HMO & Network (HMO)
- Choice POS II
- Kaiser Permanente Select - Added Choice
- IH-Indemnity
- Anthem Federal Employee Program Basic
- Magellan Complete Care of VA - VA Medicaid MCO
- Mamsi Life & Health (Indem./PPO)
- CareFirst Blue Choice Opt Out Open Access
- Anthem BCBS Medi Blue Plus
- Choice POS
- UHC Group Medicare Advantage Plans (HMO, POS, PPO)
- Anthem BCBS of VA Key Care POS/PPO/Indemnity
- AMERIVANTAGE/Amerigroup Community Care
- Sentara Health
- NYC Medicare Advantage Plus
- Anthem BCBS of VA HealthKeepers (HMO)
- Kaiser Permanente Signature
- United Healthcare Select Plus (POS)
- IH-Open Network Only Plus
- IH-Open POS II
- Blue Choice Advantage
- Alterwood Advanatge HMO & DSNP Plans
- United Healthcare Select HMO - EPO/NPP
- United HealthCare Community Plan - Maryland Health Choice Program
- Johns Hopkins Advantage MD PPO
- CareFirst Federal Employee Program (Std. & Basic PPO)
- Aetna Advantage 5750
- Cigna True Choice Medicare (PPO)
- MedStar Family Choice - Maryland Health Choice
- Choice Care Network/HUMANA (PPO)
- TRICARE East Select
- Humana Medicare Advantage - PPO
- Advantra Platinum (PPO)
- Aetna HMO
- Aetna Managed Choice Open Access (POS)
- TriWest Healthcare Alliance
- MedStar Family Choice DC Healthy Families
- HighMark
- United Healthcare Choice Plus Cardiac Global
Education
Board Certification: American Board of Internal Medicine, Internal Medicine
Residency: National Institutes of Health (2017)
Fellowship: National Institutes of Health (2017)
Residency: University of Minnesota (2014)
Residency: University of Minnesota GME (2014)
Medical School: Sungkyunkwana University (2007)
Hospital affiliations
News and publications
https://www.cbsnews.com/news/fda-looks-to-help-more-cancer-patients-access-experimental-drugs-compassionate-use/
https://undark.org/2018/09/10/fda-drugs-accelerated-approval/
https://thetranslationalscientist.com/disease-area/proving-the-worth-of-icis
https://www.healio.com/news/hematology-oncology/20190208/immune-checkpoint-inhibitors-benefit-patients-with-hiv-advanced-cancer
Original papers in refereed journals
1. Yeung V, Kim C, Kiedrowski LA, Liu SV, Reuss JE. Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report. Translational Lung Cancer Research. 2022;11(1):111.
2. Williams RM, Kareff SA, Sackstein P, Roy T, Luta G, Kim C, Taylor KL, Tammemagi MC. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review. Lung Cancer. 2022;169:55-60. Epub 2022/06/02. doi: 10.1016/j.lungcan.2022.05.008. PubMed PMID: 35644087; PMCID: PMC9248363.
3. Wilgucki M, Yeung V, Ho G, Bravo Montenegro GL, Jones G, Reuss JE, Liu SV, Kim C. Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report. JTO Clin Res Rep. 2022;3(10):100396. Epub 2022/10/04. doi: 10.1016/j.jtocrr.2022.100396. PubMed PMID: 36188633; PMCID: PMC9516460.
4. Sirgi Y, Krochmal R, Fleury CM, Holmes M, Dewitt CA, Cardis M, Kim C. Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment. Clin Lung Cancer. 2022. Epub 2022/06/15. doi: 10.1016/j.cllc.2022.05.011. PubMed PMID: 35701321.
5. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M. Characterization of MET Exon 14 Skipping Alterations (METex14) in Non-Small Cell Lung Cancer (NSCLC) and Identification of Potential Therapeutic Targets using Whole Transcriptome Sequencing (WTS). JTO Clinical and Research Reports. 2022:100381.
6. Joshi I, Peravali M, Geng X, Rao S, Chen KY, Veytsman I, Giaccone G, Liu SV, Kim C. Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. Clin Lung Cancer. 2022;23(5):438-45. Epub 2022/06/02. doi: 10.1016/j.cllc.2022.03.010. PubMed PMID: 35649819.
7. Zhang D, Tailor TD, Kim C, Atkins MB, Braithwaite D, Akinyemiju T. Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. Journal of Immunotherapy. 2021;44(5):198-203.
8. von Buttlar X, Reuss JE, Liu SV, Kim C. EML4-ALK rearrangement as a mechanism of resistance to osimertinib in metastatic lung adenocarcinoma: A Case report. JTO Clinical and Research Reports. 2021;2(6):100179.
9. Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci Transl Med. 2021;13(578). Epub 2021/01/29. doi: 10.1126/scitranslmed.abc7488. PubMed PMID: 33504652.
10. Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021;9(7). Epub 2021/08/01. doi: 10.1136/jitc-2021-002855. PubMed PMID: 34330765; PMCID: PMC8327834.
11. Rehman M, Kim C, Reuss JE, Kiedrowski LA, Garg RJ, Liu SV. Divergent RET-and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report. JCO Precision Oncology. 2021;5:939-42.
12. Peravali M, Joshi I, Ahn J, Kim C. A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep. 2021;2(3):100141. Epub 2021/01/14. doi: 10.1016/j.jtocrr.2020.100141. PubMed PMID: 33437971; PMCID: PMC7790456.
13. Peravali M, Ahn J, Chen K, Rao S, Veytsman I, Liu SV, Kim C. Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer. Oncologist. 2021. Epub 2021/04/13. doi: 10.1002/onco.13787. PubMed PMID: 33844354.
14. Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES. The Effects of HER2 alterations in EGFR mutant non-small cell lung cancer. Clinical Lung Cancer. 2021.
15. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021;160:92-8. Epub 2021/09/06. doi: 10.1016/j.lungcan.2021.08.010. PubMed PMID: 34482103.
16. McGunigal M, Margolis M, Forsthoefel M, Singh T, Amarell K, Deblois D, Campbell L, Kim C, Liu S, Bergquist PJ. Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. Acta Oncologica. 2021:1-4.
17. Kim C, Xi L, Cultraro CM, Wei F, Jones G, Cheng J, Shafiei A, Pham TH-T, Roper N, Akoth E. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma. Cancers. 2021;13(13):3342.
18. Kim C, Liu SV, Crawford J, Torres T, Chen V, Thompson J, Tan M, Esposito G, Subramaniam DS, Giaccone G. A Phase I Trial of Dasatinib and Osimertinib in TKI Naive Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. Front Oncol. 2021;11:728155. Epub 2021/09/28. doi: 10.3389/fonc.2021.728155. PubMed PMID: 34568058; PMCID: PMC8457399.
19. Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clinical and Research Reports. 2021;2(4):100149.
20. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Jr., Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021. Epub 2021/09/15. doi: 10.1158/1535-7163.MCT-21-0201. PubMed PMID: 34518295.
21. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021;12(25):2449.
22. Giaccone G, Kim C. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol. 2021;16(3):483-5. Epub 2020/11/29. doi: 10.1016/j.jtho.2020.11.003. PubMed PMID: 33248322.
23. Estrada-Bernal A, Le AT, Doak AE, Tirunagaru VG, Silva S, Bull MR, Smaill JB, Patterson AV, Kim C, Liu SV, Doebele RC. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021;27(5):1463-75. Epub 2020/12/24. doi: 10.1158/1078-0432.CCR-20-3555. PubMed PMID: 33355298; PMCID: PMC7926264.
24. Dudnik E, Kareff S, Moskovitz M, Kim C, Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. Journal for immunotherapy of cancer. 2021;9(2).
25. Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020;132:168-75. Epub 2020/05/07. doi: 10.1016/j.ejca.2020.03.015. PubMed PMID: 32375103.
26. Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, Kim C, Weiner LM. Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. J Cancer Surviv. 2020;14(1):53-8. Epub 2019/11/07. doi: 10.1007/s11764-019-00826-1. PubMed PMID: 31686365.
27. Roper N, Brown A-L, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, Meskini RE, Ohler ZW, Maity TK, Venugopala A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Pachenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Reports Medicine. 2020;1(1).
28. Peravali M, Wang H, Kim C, Veytsman I. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Curr Oncol Rep. 2020;22(12):119. Epub 2020/09/19. doi: 10.1007/s11912-020-00981-0. PubMed PMID: 32945977.
29. Li N, Guha U, Kim C, Ye L, Cheng J, Li F, Chia D, Wei F, Wong DT. Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports. Frontiers in oncology. 2020;10:1240.
30. Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, Giaccone G. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2). Epub 2020/07/04. doi: 10.1136/jitc-2020-000980. PubMed PMID: 32616557; PMCID: PMC7333915.
31. Kareff SA, Lischalk JW, Krochmal R, Kim C. Abscopal effect in pulmonary carcinoid tumor following ablative stereotactic body radiation therapy: a case report. J Med Case Rep. 2020;14(1):177. Epub 2020/10/05. doi: 10.1186/s13256-020-02512-8. PubMed PMID: 33010806; PMCID: PMC7532944.
32. Farid S, Latif H, Nilubol C, Kim C. Immune Checkpoint Inhibitor-induced Fanconi Syndrome. Cureus. 2020;12(4):e7686. doi: 10.7759/cureus.7686.
33. Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7(1):353. Epub 2019/12/19. doi: 10.1186/s40425-019-0771-1. PubMed PMID: 31847881; PMCID: PMC6918622.
34. Desai S, Kim C, Veytsman I. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give? Curr Oncol Rep. 2019;21(9):84. Epub 2019/08/15. doi: 10.1007/s11912-019-0835-x. PubMed PMID: 31410582.
35. Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019;5(7):1049-54. Epub 2019/02/08. doi: 10.1001/jamaoncol.2018.6737. PubMed PMID: 30730549.
36. Al-Shbool G, Latif H, Farid S, Wang S, Ahn J, Giaccone G, Kim C. Publication Rate and Characteristics of Lung Cancer Clinical Trials. JAMA Netw Open. 2019;2(11):e1914531. Epub 2019/11/07. doi: 10.1001/jamanetworkopen.2019.14531. PubMed PMID: 31693119; PMCID: PMC6865260.
37. Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347-55. Epub 2018/02/06. doi: 10.1016/S1470-2045(18)30062-7. PubMed PMID: 29395863.
38. Valle L, Thomas J, Kim C, Szabo E, Brown GT, Citrin D, Rajan A. Hepatoid adenocarcinoma of the lung metastasizing to the tonsil. Mol Clin Oncol. 2017;6(5):705-7. Epub 2017/05/23. doi: 10.3892/mco.2017.1215. PubMed PMID: 28529745; PMCID: PMC5431682.
39. Gharwan H, Kim C, Thomas A, Berman A, Kim SA, Biassou N, Steinberg SM, Rajan A. Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. Transl Lung Cancer Res. 2017;6(5):588-99. Epub 2017/11/09. doi: 10.21037/tlcr.2017.08.06. PubMed PMID: 29114474; PMCID: PMC5653528.
40. Del Rivero J, Kim C, Eid M, Ahlman MA, Nieman LK, Rajan A. Thymic Hyperplasia after Treatment of ACTH-Dependent Cushing's Syndrome Can Be Mistaken for a Thymic Epithelial Tumor. J Thorac Oncol. 2017;12(4):e29-e32. Epub 2016/11/21. doi: 10.1016/j.jtho.2016.11.2215. PubMed PMID: 27865872.
41. Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Dominguez E, Garcia-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PLoS One. 2017;12(10):e0175484. Epub 2017/10/06. doi: 10.1371/journal.pone.0175484. PubMed PMID: 28981524; PMCID: PMC5628783.
42. Kim C, Zhang X, Chan AT, Sesso HD, Rifai N, Stampfer MJ, Ma J. Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study. Cancer Epidemiol. 2016;44:65-70. Epub 2016/08/10. doi: 10.1016/j.canep.2016.07.012. PubMed PMID: 27504605; PMCID: PMC5821121.
43. Kim C, Rajan A, DeBrito PA, Giaccone G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016;5(6):720-6. Epub 2017/02/06. doi: 10.21037/tlcr.2016.11.06. PubMed PMID: 28149767; PMCID: PMC5233874.
44. Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc. 2016. Epub 2016/05/30. doi: 10.1016/j.mayocp.2016.02.012. PubMed PMID: 27236424; PMCID: PMC5104665.
45. Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015;175(8):1389-98. Epub 2015/06/23. doi: 10.1001/jamainternmed.2015.2829. PubMed PMID: 26098871.
46. Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015;175(12):1992-4. Epub 2015/10/27. doi: 10.1001/jamainternmed.2015.5868. PubMed PMID: 26502403.
47. Kim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer Res. 2015;35(1):301-9. Epub 2015/01/01. PubMed PMID: 25550564.
48. Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res. 2015;25(1):75-9. Epub 2014/11/27. doi: 10.1097/CMR.0000000000000133. PubMed PMID: 25426645.
49. Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27-32. Epub 2013/05/30. doi: 10.1161/HYPERTENSIONAHA.113.01453. PubMed PMID: 23716587; PMCID: PMC3729220.
50. Paik KH, Lee MK, Jin DK, Kang HW, Lee KH, Kim AH, Kim C, Lee JE, Oh YJ, Kim S, Han SJ, Kwon EK, Choe YH. Marked suppression of ghrelin concentration by insulin in Prader-willi syndrome. J Korean Med Sci. 2007;22(2):177-82. Epub 2007/04/24. doi: 10.3346/jkms.2007.22.2.177. PubMed PMID: 17449920; PMCID: PMC2693578.
Reviews or editorials in refereed journals
1. Jonna S, Reuss JE, Kim C, Liu SV. Oral Chemotherapy for Treatment of Lung Cancer. Frontiers in Oncology. 2020;10:793.
2. Friedlaender A, Kim C, Addeo A. Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic. Frontiers in Oncology. 2020;10:862.
3. Kim C, Liu S. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Oxford University Press; 2019.
4. Kim C, Giaccone G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(6):348-9. Epub 2018/03/31. doi: 10.1038/s41571-018-0008-0. PubMed PMID: 29599475.
5. Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs. 2018;27(1):17-30. Epub 2017/12/09. doi: 10.1080/13543784.2018.1415324. PubMed PMID: 29216787.
6. Kim C, Giaccone G. The role of immune checkpoint blockade for treatment of thymic epithelial tumors—a delicate balance between efficacy and side effects2018.
7. Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):179-93. Epub 2016/10/27. doi: 10.1016/j.jtho.2016.10.012. PubMed PMID: 27780780.
8. Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother. 2016;12(9):2219-31. Epub 2016/05/03. doi: 10.1080/21645515.2016.1175694. PubMed PMID: 27135835; PMCID: PMC5027703.
9. Kim C, Giaccone G. Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. Ann Transl Med. 2016;4(23):466. Epub 2017/01/17. doi: 10.21037/atm.2016.11.48. PubMed PMID: 28090522; PMCID: PMC5220042.